邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

瑞德西韦治疗冠状病毒感染的研究进展

靳凡,  谢静,  陈锐,  王焕玲

downloadPDF
文章导航 > 协和医学杂志  > 2020 >  11(6): 659-664
靳凡, 谢静, 陈锐, 王焕玲. 瑞德西韦治疗冠状病毒感染的研究进展[J]. 协和医学杂志, 2020, 11(6): 659-664. doi: 10.3969/j.issn.1674-9081.20200034
引用本文: 靳凡, 谢静, 陈锐, 王焕玲. 瑞德西韦治疗冠状病毒感染的研究进展[J]. 协和医学杂志, 2020, 11(6): 659-664. doi: 10.3969/j.issn.1674-9081.20200034
shu
JIN Fan, XIE Jing, CHEN Rui, WANG Huan-ling. Progress of Remdesivir in the Treatment of Coronavirus Infection[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 659-664. doi: 10.3969/j.issn.1674-9081.20200034
Citation: JIN Fan, XIE Jing, CHEN Rui, WANG Huan-ling. Progress of Remdesivir in the Treatment of Coronavirus Infection[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 659-664. doi: 10.3969/j.issn.1674-9081.20200034
shu

瑞德西韦治疗冠状病毒感染的研究进展

doi: 10.3969/j.issn.1674-9081.20200034
  • 1.

    中国医学科学院 北京协和医学院 北京协和医院 感染内科，北京 100730

  • 2.

    中国医学科学院 北京协和医学院 北京协和医院 临床药理研究中心，北京 100730

基金项目: 

国家“十三五”重大新药创制专项子课题“创新药物临床评价示范性平台建设” 2019ZX09734001

详细信息
    通讯作者:

    王焕玲  电话：010-69158360，E-mail：wanghuanling@pumch.cn

  • 中图分类号: R51;R18

Progress of Remdesivir in the Treatment of Coronavirus Infection

  • 1.

    Department of Infection Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 2019年12月，由2019新型冠状病毒(2019-novel coronavirus，2019-nCoV)感染导致的新型冠状病毒肺炎(coronavirus disease 2019，COVID-19)于我国武汉暴发，成为全球近十几年来，继严重急性呼吸综合征(severe acute respiratory syndrome，SARS)和中东呼吸综合征(Middle East respiratory syndrome，MERS)之后第3次暴发的冠状病毒疫情。本次COVID-19疫情传播迅速、广泛，病毒传染性强，但目前尚无针对2019-nCoV的特异性药物。瑞德西韦(remdesivir)属于核苷类似物抗病毒药，在细胞实验和动物模型上均显示出抗SARS-CoV和抗MERS-CoV活性，且在治疗埃博拉病毒感染的多中心随机对照临床试验中未见明显不良反应。因此，该药被认为是治疗2019-nCoV感染极有潜力的药物。本文对瑞德西韦治疗CoV感染的研发历程和潜在临床应用作一综述。
    Abstract: In December 2019, the outbreak of coronavirus disease 2019(COVID-19)occurred in Wuhan, China. It became the third outbreak of coronavirus infection after severe acute respiratory syndrome(SARS)and Middle East respiratory syndrome(MERS)in the past decade. COVID-19 is caused by 2019-novel coronavirus(2019-nCoV)infection that has spread rapidly and extensively.2019-nCoV is highly contagious, but there is no specific antiviral drug for coronavirus at present. Remdesivir, a nucleoside analogue, showed anti-SARS-CoV and anti-MERS-CoV activities in vitro and in animal models, and showed no obvious adverse reaction in the multicenter, randomized, controlled clinical trial of Ebola virus infection. Remdesivir is considered to be the great promising drug for treating 2019-nCoV infection. This article reviewed the research history and potential clinical applications of remdesivir in the treatment of coronavirus infection.
    利益冲突  无
    • HTML全文
    • 参考文献(25)
  • [1] van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans[J]. mBio, 2012, 3:e00473-e00412.
    [2] Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle[J]. J Med Virol, 2020, 92:401-402.
    [3] Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States[J]. N Engl J Med, 2020, 382:929-936.
    [4] Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses[J]. Sci Transl Med, 2017, 9:eaal3653.
    [5] Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral remdesivir(GS-5734)Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease[J]. mBio, 2018, 9:e00221-e00218.
    [6] Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. Nat Commun, 2020, 11:222.
    [7] World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 [EB/OL]. http://www.who.int/csr/sars/country/table2004_04_21/en/.
    [8] World Health Organization. MERS situation update 2019[EB/OL]. http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.
    [9] Chen L, Liu W, Zhang Q, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak[J]. Emerg Microbes Infect, 2020, 9:313-319.
    [10] Woo PC, Lau SK, Huang Y, et al. Coronavirus diversity, phylogeny and interspecies jumping[J]. Exp Biol Med(Maywood), 2009, 234:1117-1127.
    [11] Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus[J]. Microbiol Mol Biol Rev, 2005, 69:635.
    [12] Bonavia A, Zelus BD, Wentworth DE, et al. Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E[J]. J Virol, 2003, 77:2530-2538.
    [13] Zumla A, Chan JF, Azhar EI, et al. Coronaviruses-drug discovery and therapeutic options[J]. Nat Rev Drug Discov, 2016, 15:327-347.
    [14] Chu CK, Gadthula S, Chen X, et al. Antiviral activity of nucleoside analogues against SARS-coronavirus(SARS-coV)[J]. Antivir Chem Chemother, 2006, 17:285-289.
    [15] Cho A, Saunders OL, Butler T, et al. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7, 9-dideazaadenosine C-nucleosides[J]. Bioorg Med Chem Lett, 2012, 22, 2705-2707.
    [16] de Wilde AH, Snijder EJ, Kikkert M, et al. Host Factors in Coronavirus Replication[J]. Curr Top Microbiol Immunol, 2018, 419:1-42.
    [17] Sims AC, Baric RS, Yount B, et al. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia:role of ciliated cells in viral spread in the conducting airways of the lungs[J]. J Virol, 2005, 79:15511-15524.
    [18] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro[J]. Cell Res, 2020, 130:269-271.
    [19] World Health Organization. Summaries of evidence from selected experimental therapeutics[EB/OL]. https://www.who.int/ebola/drc-2018/treatments-approved-for-compassi-onate-use-update/en/.
    [20] Mulangu S, Dodd LE, Davey RT, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics[J]. N Engl J Med, 2019, 381:2293-2303.
    [21] Chan JFW, Yuan SF, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission:a study of a family cluster[J]. Lancet, 2020, 395:514-523.
    [22] Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395:497-506.
    [23] Clinical Trials. Severe 2019-nCoV Remdesivir RCT[EB/OL]. https://clinicaltrials.gov/ct2/show/NCT04257656?term=remdesivir&draw=2&rank=1.
    [24] Clinical Trials. Mild/Moderate 2019-nCoV Remdesivir RCT[EB/OL]. https://clinicaltrials.gov/ct2/show/NCT04252664?term=remdesivir&draw=2&rank=2.
    [25] Clinical Trials. Adaptive COVID-19 Treatment Trial[EB/OL]. https://clinicaltrials.gov/ct2/show/NCT04280705?cond=Adaptive+COVID-19+Treatment+Trial&draw=2&rank=1.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  283
  • HTML全文浏览量:  70
  • PDF下载量:  26
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-02-17
  • 录用日期:  2020-02-23
  • 网络出版日期:  2020-02-28
  • 刊出日期:  2020-11-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！